APhA2026 Highlights GLP-1 Expansion into Kidney Disease and Sleep Apnea
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.